Trial Profile
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Apremilast (Primary) ; Corticosteroids
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms ESTEEM-2
- Sponsors Amgen; Celgene Corporation
- 21 Mar 2023 Results From ESTEEM 1 and ESTEEM 2 analyzing efficacy of Apremilast in Patients With Moderate-to-Severe Plaque Psoriasis Across Weight and BMI Subgroups, resented at the American Academy of Dermatology annual Meeting 2023
- 25 Apr 2021 Results assessing APR on scalp and nail psoriasis in patients with and without dermatology investigator-reported PsA history in moderate-to-severe psoriasis from ESTEEM 1 & 2 and LIBERATE trials presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 12 Sep 2018 According to a Celgene Corporation media release, results of a post hoc sub-analysis of data from the ESTEEM 1 and 2 and phase 4 UNVEIL trials were presented at the 27th European Academy of Dermatology and Venereology (EADV) Congress.